In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

ABSTRACT We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%),...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2008-11, Vol.32, p.S188-S191
Main Authors: Liu, Jien-Wei, Wang, Lih-Shinn, Cheng, Yu-Jen, Hsu, Gwo-Jong, Lu, Po-Liang, Liu, Yung-Ching, Chen, Chih-Ming, Lee, Chun-Ming, Sun, Wu, Jang, Tsrang-Neng, Chiang, Ping-Cherng, Chuang, Yin-Ching, Lin, Hsiu-Chen, Shi, Zhi-Yuan, Kung, Hsiang-Chi, Huang, Cheng-Hua, Tsao, Shih-Ming, Lu, Chin-Te, Liao, Chun-Hsing, Hsueh, Po-Ren
Format: Article
Language:English
Subjects:
Acinetobacter baumannii
Acinetobacter baumannii - drug effects
Acinetobacter baumannii - isolation & purification
Acinetobacter Infections - microbiology
Anti-Bacterial Agents - pharmacology
Antibacterial drug resistance
Humans
Infectious Disease
Microbial Sensitivity Tests
Minocycline - analogs & derivatives
Minocycline - pharmacology
Taiwan
Tigecycline
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration ( MIC ) of tigecycline ranged from 0.6 to 16 μg/mL ( MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.
ISSN:0924-8579
1872-7913
DOI:10.1016/S0924-8579(08)70026-8